TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Correlation between blood markers and primary tumor markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hamilton Rating Scale for Depression (HAMD17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mass balance recovery of radiolabelled Debio 1450
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Routes of metabolism and excretion of radiolabelled Debio 1450
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole blood and plasma partitioning of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically significant change in vital signs, ECG, and laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of propofol dose used in sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of failure of the Enbrel® SureClick™ Auto-injector
Endpoint domain: Adverse events/effects
Primary endpoint: Concentrations of doripenem in plasma, epithelial lining fluid, and alveolar macrophages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total clearance of Microfilariae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and tolerability of very low dose LSD
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Human Serum Bactericidal Activity Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of precariousness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity and specificity of galactomannan ELISA and real time PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Positive and negative predictive values of IA screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in heart rate variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in local blood perfusion index (BPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in klotho levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closeness in the Child Parent Relationship
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of composite endpoint of cardiac death, stent thrombosis, re-PCI, Target Vessel Revascularization and bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Blood Pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost of complication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of primary treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Aggregate adherence to pharmacotherapy rules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Css,Max for Day 4 to Day 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of AUCss for Day 4 to Day 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-year Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-year Waist Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total WOMAC Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of H. pylori infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of gastro-esophageal reflux (GER) by 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Continuous esophageal pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Successful introduction, positioning and removal of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sensitivity of ICG uptake and expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: average frequency of bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: socioeconomic status of claimants
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of hyperoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Hernia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from Baseline SCORAD Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized Concentrations Of Non-ceruloplasmin-bound Copper (NCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Image Quality of Esophageal Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mental performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Phase 2 kinetics in COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: t for V'E, V'CO2, and V'O2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Half-times for HR and O2 pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to recurrence of detrusor overactivity incontinence symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of renal denervation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of renal denervation
Endpoint domain: Adverse events/effects
Primary endpoint: Regression rate in cervical intraepithelial neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of MRI Scans from Pacemakers or CRT-Ps with Sufficient Image Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of MRI Scans from ICDs or CRT-Ds with Sufficient Image Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose
Endpoint domain: Adverse events/effects
Endpoint subdomain: Dose Limited Toxicity
Primary endpoint: Patient/family satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean duration of stent patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mobility status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FEV1% (forced expiratory volume in 1 second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of POAF
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Versus Time Curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Events of Atrial Fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NAFLD severity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the level of T lymphocyte subsets CD3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the level of T lymphocyte subsets CD4+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the level of T lymphocyte subsets CD8+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ratio of CD4+/CD8+ T lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hot flashes frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Luteinizing hormone levels (urine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Coronary calcium score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of circulating plasmablasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients deceased
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in the Disease Activity Score (C-reactive protein) [DAS28(CRP)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer healing proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoas tendinitis development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Degree of deformity valgus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Subtalar range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HBV (HBsAg) recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plaque composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of peripheral arterial desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Minimum Luminal Area (MLA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Vaccine Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduced dentin hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with TIMI grade 2 or 3 flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C-Reactive Protein concentration in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ultrasensitive HIV-1 RNA levels in cerebrospinal fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the Curve (AUC) of enalapril and enalaprilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Concentration (Cmax) of enalapril and enalaprilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to Maximum Concentration (Tmax) of enalapril and enalaprilat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain evaluation using visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Question-to-question agreement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Virological clearance rate at day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Virological clearance rate at day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Virological clearance rate at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: GI tolerance via stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mechanical ventilation
Endpoint domain: Mortality/survival
Primary endpoint: Visual Analog Scale (VAS) of Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: CD64 count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Unplanned urgent visits to the health care system
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recommended phase II dose of durvalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Developing a New MS Relapse and/or MRI Brain Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: all cause neonatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Referrals to Genetic Counseling
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Surgical revision rate
Endpoint domain: Adverse events/effects
Primary endpoint: Skin Sympathetic Nerve Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Compliance with WHO recommendations on diet and/or exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Responsiveness of endurance tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antiseptic properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Problem Solving Inventory-Revised (SPSI-R)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of subjects with sUA level < 6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Causal relationships of oxygenated and de-oxygenated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of cardiovascular death or non-fatal heart failure events
Endpoint domain: Mortality/survival
Primary endpoint: brachial ankle pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: P50 auditory evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in optical density of macular pigment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Six-Minute Walk Test (6MWT) at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Percent Predicted Forced Vital Capacity (FVC) at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Summary of Participants Reporting Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of functional score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Continuous use of anthracycline-containing chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tumor tissue molecular profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: complication rate at 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with osteoporosis that are appropriately treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in internal body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Pediatric Quality of Life Inventory (PedsQL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in Revised Child Anxiety and Depression Scale (RCADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Corticospinal excitability profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absence of Major Product Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of severe paradoxical reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-time Profile (AUC24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yale Brown Obsessive Compulsive Scale (Y-BOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant-perceived Cooling Sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleasantness ratings of social touch
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood-oxygen-level dependent signal in response to social touch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anesthetic Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in voice and facial symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of contaminated personnel
Endpoint domain: Adverse events/effects
Primary endpoint: number of transfusions of allogeneic RBC from surgery up to day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: total blood loss from surgery to day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to the maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the first extrapolated non-zero concentration (Tlag)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to the maximum concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants with a positive T-bet expressing Flu-specific B cell subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total epidural analgesic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CTX-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine CTX-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: indices of nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Neurogenic inflammation-QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neurogenic inflammation-Short Form (36) Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Neurogenic inflammation- Visual Analog pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to localize the lumbar plexus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications from lumbar plexus blockade
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Difference of Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference of In Vivo Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Difference of Terminal Half-Life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device or procedure related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial blood sugar level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change of the radial artery diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of cases of amblyopia detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical Case Completion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lung involvement in Ulcerative colitis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in unconjugated hyperbilirubinaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incorporation of 13C3 cholesterol into plasma cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: trauma admissions
Endpoint domain: Mortality/survival
Primary endpoint: Urinary and Fecal Excretion of LY2603618 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in eating disorder severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental biofilm reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of (1'-OH) Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfusion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Psychological pain reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hamilton depression rating scale (HAM-D) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing